---
title: "Most FDA advisers say peptides like BPC-157 -2-"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293672037.md"
description: "Most FDA advisers oppose peptides like BPC-157. Semax, approved in Russia for stroke and optic nerve conditions, is marketed online for ADHD and Alzheimer's. The FDA concerns include lack of container information for compounding pharmacies."
datetime: "2026-07-23T21:55:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293672037.md)
  - [en](https://longbridge.com/en/news/293672037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293672037.md)
generator: "portal-rs"
---

# Most FDA advisers say peptides like BPC-157 -2-

Semax: Semax is the only peptide under discussion to be formally approved in another country. It's cleared for use in Russia to treat stroke or optic-nerve conditions, though it's marketed online for dozens of conditions, like ADHD and Alzheimer's disease. It is dispensed in nasal drops. One of the FDA's concerns is that it doesn't have any information about the containers that would be used by compounding pharmacies to dispense the medication.

-Jaimy Lee

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-23-26 1755ET

## Related News & Research

- [Revolut wins conditional US banking license](https://longbridge.com/en/news/297940570.md)
- [Why Dell's Blowout Q2 Gives Investors No Reason to Stay on the Sidelines](https://longbridge.com/en/news/297913696.md)
- [BUZZ-Street View: Broadcom's pipeline soothes AI spending doubts](https://longbridge.com/en/news/297905938.md)
- [SpaceX Was ‘Nowhere’ in AI 6 Months Ago — Now It’s an Anthropic Rival After the $60 Billion Cursor Deal, Says Oppenheimer](https://longbridge.com/en/news/297900623.md)
- [Next Phase Of AI–Elon Musk’s 1 Billion Robots](https://longbridge.com/en/news/297821554.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**